These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29199852)

  • 21. Safety of low-dose dabigatran in patients with atrial fibrillation and mild renal insufficiency.
    Fukaya H; Niwano S; Oikawa J; Nishinarita R; Horiguchi A; Nakamura H; Fujiishi T; Igarashi T; Ishizue N; Yoshizawa T; Satoh A; Kishihara J; Murakami M; Ako J
    J Cardiol; 2017 Mar; 69(3):591-595. PubMed ID: 27377855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
    Brunetti L; Chen C; White J
    Consult Pharm; 2014 Mar; 29(3):169-78. PubMed ID: 24589766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Value of Red Blood Cell Distribution Width on Bleeding Events in Nonvalvular Atrial Fibrillation Patients Taking Dabigatran (110 mg b.i.d.) after Catheter Ablation.
    Zhang Q; Qin Y; Zhao DS; Zhao HP; Zhou L
    Cardiology; 2017; 136(4):215-221. PubMed ID: 27802430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
    Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
    Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia.
    Beshir SA; Chee KH; Lo YL
    Int J Clin Pharm; 2016 Oct; 38(5):1182-90. PubMed ID: 27450507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcome in patients with non-valvular atrial fibrillation on dabigatran: a prospective cohort study.
    Verdecchia P; Vedovati MC; Conti S; Giustozzi M; Aita A; Molini G; Angeli F; Turturiello D; Becattini C; Cavallini C; Agnelli G
    Expert Opin Drug Saf; 2018 Nov; 17(11):1063-1069. PubMed ID: 30260252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
    Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
    BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 32. Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF Registry.
    Paquette M; França LR; Teutsch C; Diener HC; Lu S; Dubner SJ; Ma CS; Rothman KJ; Zint K; Halperin JL; Olshansky B; Huisman MV; Lip GYH; Nieuwlaat R
    Am J Cardiol; 2020 Feb; 125(3):383-391. PubMed ID: 31785775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience.
    Kumar R; Smith RE; Henry BL
    J Intensive Care Med; 2015 Dec; 30(8):462-72. PubMed ID: 24668159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
    Connolly SJ; Wallentin L; Ezekowitz MD; Eikelboom J; Oldgren J; Reilly PA; Brueckmann M; Pogue J; Alings M; Amerena JV; Avezum A; Baumgartner I; Budaj AJ; Chen JH; Dans AL; Darius H; Di Pasquale G; Ferreira J; Flaker GC; Flather MD; Franzosi MG; Golitsyn SP; Halon DA; Heidbuchel H; Hohnloser SH; Huber K; Jansky P; Kamensky G; Keltai M; Kim SS; Lau CP; Le Heuzey JY; Lewis BS; Liu L; Nanas J; Omar R; Pais P; Pedersen KE; Piegas LS; Raev D; Smith PJ; Talajic M; Tan RS; Tanomsup S; Toivonen L; Vinereanu D; Xavier D; Zhu J; Wang SQ; Duffy CO; Themeles E; Yusuf S
    Circulation; 2013 Jul; 128(3):237-43. PubMed ID: 23770747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
    Larsen TB; Rasmussen LH; Skjøth F; Due KM; Callréus T; Rosenzweig M; Lip GY
    J Am Coll Cardiol; 2013 Jun; 61(22):2264-73. PubMed ID: 23562920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bleeding incidence and real-life prescribing practices with dabigatran use in an acute care setting.
    Tran TH; Nguyen C; Lam T; Campbell P
    Consult Pharm; 2014 Nov; 29(11):735-40. PubMed ID: 25369188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectivity of hemodialysis in acute gastrointestinal bleeding associated with dabigatran overdose.
    Kilit C; Erarslan S; Pasali Kilit T
    Acta Gastroenterol Belg; 2017; 80(2):322. PubMed ID: 29560702
    [No Abstract]   [Full Text] [Related]  

  • 38. [Dabigatran specific antidote: new safety level in oral anticoagulation].
    MMW Fortschr Med; 2015 Nov; 157(19):78-9. PubMed ID: 26953416
    [No Abstract]   [Full Text] [Related]  

  • 39. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
    Waks JW; Zimetbaum PJ
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
    Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.